Migraine trials in Canada

In Canada 20 Also abroad 249

20 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Study of EVO756 in Adults With Migraine
Where
Québec
Age
18 years to 64 years
People
330 worldwide
Run by
Evommune, Inc.
See details and how to joinNCT07616128
Phase 3Taking people
Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)
Where
Toronto
Age
18 years to 65 years
People
80
Run by
Sunnybrook Health Sciences Centre
See details and how to joinNCT07191145
Phase 3Taking people
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Where
Kelowna BC, Sherbrooke
Age
6 years to 17 years
People
2,100 worldwide
Run by
Pfizer
See details and how to joinNCT04649242 · EU 2024-512743-23-00
Phase 3Taking people
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
Where
Ajax, Edmonton, London, Penticton, Victoria
Age
12 years to 17 years
People
285 worldwide
Run by
H. Lundbeck A/S
See details and how to joinNCT04965675 · EU 2024-510656-13-00
Phase 3Taking people
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Where
Vancouver
Age
6 years to 17 years
People
640 worldwide
Run by
Pfizer
See details and how to joinNCT05156398 · EU 2024-512382-13-00
Phase 3Taking people
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
Where
Ajax, London, Victoria
Age
6 years to 17 years
People
600 worldwide
Run by
H. Lundbeck A/S
See details and how to joinNCT05164172 · EU 2022-502917-27-00
Phase 3Taking people
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
Where
Ajax, London, Penticton, Victoria
Age
6 years to 17 years
People
315 worldwide
Run by
H. Lundbeck A/S
See details and how to joinNCT05897320 · EU 2022-502538-14-00
Phase 3Taking people
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Where
London, Montreal
Age
12 years to 17 years
People
420 worldwide
Run by
AbbVie
See details and how to joinNCT06810505 · EU 2024-513836-28-00
Phase 3Taking people
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Where
Edmonton, London, Montreal
Age
6 years to 17 years
People
450 worldwide
Run by
AbbVie
See details and how to joinNCT05711394 · EU 2022-501100-94-00
Phase 3Enrolling by invitation
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
Where
New Westminster, Surrey
Age
19 years to 75 years
People
102
Run by
Dr George Medvedev
See details and how to joinNCT06428838
No phaseNot yet taking people in Canada
Neuromodulation During the Prodrome to Prevent Disabling Migraine Attacks in Youth
Where
Calgary
Age
8 years to 18 years
People
30
Run by
University of Calgary
See details and how to joinNCT07772427
Phase 3Taking people
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Where
Brampton, Halifax, Kelowna, Lévis, Red Deer, Sarnia, Surrey
Age
18 years to 45 years
People
723 worldwide
Run by
Pfizer
See details and how to joinNCT06641466 · EU 2024-517121-10-00
No phaseNot yet taking people in Canada
Self-Hypnosis Training for Migraine Management (HYlaMI): A Pilot and Proof-of-Concept Study
Where
Montreal
Age
18 years and over
People
40
Run by
Ciusss de L'Est de l'Île de Montréal
See details and how to joinNCT07644299
Phase 3Taking people
Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches
Where
Toronto
Age
18 years to 75 years
People
56
Run by
University Health Network, Toronto
See details and how to joinNCT05306899
Phase 2Taking people
Cannabis for the Prophylactic Treatment of Migraine
Where
Calgary
Age
25 years and over
People
72
Run by
University of Calgary
See details and how to joinNCT03972124
No phaseNot yet taking people in Canada
Exploring Mild Electrical Vestibular Stimulation as a New Treatment for Dizziness and Migraine Symptoms
Where
Calgary
Age
18 years and over
People
50
Run by
University of Calgary
See details and how to joinNCT07368140
No phaseTaking people
Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy
Where
Ottawa
Age
18 years and over
People
1,884 worldwide
Run by
AbbVie
See details and how to joinNCT05158894
No phaseNot yet taking people in Canada
Evaluation of a Mind-Body Based Approach for Chronic Pain Treatment
Where
Chilliwack
Age
19 years to 75 years
People
100
Run by
University of the Fraser Valley
See details and how to joinNCT07143396
Phase 3Enrolling by invitation
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
Where
Edmonton, Montreal
Age
6 years to 17 years
People
650 worldwide
Run by
AbbVie
See details and how to joinNCT05707949 · EU 2022-501099-24-00
Phase 2Taking people
Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial
Where
Halifax, Toronto, Vancouver
Age
14 years to 17 years
People
20
Run by
University of Manitoba
See details and how to joinNCT05337033